Hammond M Elizabeth Hale
Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT 84143, USA.
Appl Immunohistochem Mol Morphol. 2011 Dec;19(6):499-500. doi: 10.1097/PAI.0b013e31822a8eac.
This brief report compares and contrasts the American Society of Clinical Oncology/College of American Pathologists guidelines for breast cancer predictive factor testing including the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor, type 2, erbB2 Guideline published in 2007 and the recently published Guideline for Estrogen Receptor and Progesterone Receptor Testing by Immunohistochemistry, published in 2011.
本简要报告比较并对比了美国临床肿瘤学会/美国病理学家学会关于乳腺癌预测因子检测的指南,包括2007年发布的美国临床肿瘤学会/美国病理学家学会人表皮生长因子受体2型(erbB2)指南以及最近于2011年发布的免疫组织化学雌激素受体和孕激素受体检测指南。